​

Anika Therapeutics (ANIK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ANIK Stock Rating

Anika Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (50.00%), 3 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 3 3 Strong Sell Sell Hold Buy Strong Buy

ANIK Price Target Upside V Benchmarks

TypeNameUpside
StockAnika Therapeutics-
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks20.18%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$9.74$9.74$9.74
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2511---2
Sep, 2512---3
Aug, 2512---3
Jul, 2512---3
Jun, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 29, 2024StephensEqual-WeightEqual-Weighthold
Aug 14, 2023Goldman SachsBuyupgrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.69$0.29$-1.02$-5.64-----
Avg Forecast$-0.69$0.40$-0.92$-0.91$-1.45$0.12$0.68$1.07$1.42
High Forecast$-0.68$0.40$-0.91$-0.91$-1.43$0.12$1.64$1.08$1.43
Low Forecast$-0.69$0.40$-0.93$-0.92$-1.46$0.11$-0.29$1.06$1.41
Surprise %144.93%-27.50%10.87%519.78%-----

Revenue Forecast

$100M $130M $160M $190M $220M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$130.46M$147.79M$156.24M$166.66M-----
Avg Forecast$131.28M$144.03M$154.31M$165.10M$150.20M$114.50M$124.24M$214.60M$234.20M
High Forecast$131.45M$144.21M$155.32M$166.17M$151.18M$115.25M$125.05M$216.00M$235.72M
Low Forecast$131.11M$143.84M$153.30M$164.03M$149.22M$113.75M$123.43M$213.20M$232.68M
Surprise %-0.63%2.62%1.25%0.95%-----

Net Income Forecast

$-450M $-310M $-170M $-30M $110M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-23.98M$4.13M$-14.86M$-82.67M-----
Avg Forecast$-10.04M$5.81M$-241.29K$-82.67M$-21.18M$1.69M$5.25M$15.68M$20.81M
High Forecast$-10.02M$5.82M$2.52M$244.05M$-21.00M$1.70M$24.03M$15.81M$20.99M
Low Forecast$-10.06M$5.80M$-3.00M$-409.38M$-21.36M$1.67M$-4.24M$15.55M$20.64M
Surprise %138.88%-28.89%6058.25%------

ANIK Forecast FAQ

Is Anika Therapeutics stock a buy?

Anika Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Anika Therapeutics is a favorable investment for most analysts.

What is Anika Therapeutics's price target?

Anika Therapeutics's price target, set by 6 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $9.74.

How does Anika Therapeutics stock forecast compare to its benchmarks?

Anika Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (20.18%).

What is the breakdown of analyst ratings for Anika Therapeutics over the past three months?

  • October 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Anika Therapeutics’s EPS forecast?

Anika Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.45, marking a -74.29% decrease from the reported $-5.64 in 2023. Estimates for the following years are $0.12 in 2025, $0.68 in 2026, $1.07 in 2027, and $1.42 in 2028.

What is Anika Therapeutics’s revenue forecast?

Anika Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $150.2M, reflecting a -9.88% decrease from the reported $166.66M in 2023. The forecast for 2025 is $114.5M, followed by $124.24M for 2026, $214.6M for 2027, and $234.2M for 2028.

What is Anika Therapeutics’s net income forecast?

Anika Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-21.178M, representing a -74.38% decrease from the reported $-82.667M in 2023. Projections indicate $1.69M in 2025, $5.25M in 2026, $15.68M in 2027, and $20.81M in 2028.